Who is eligible for clinical trial NCT07315113?

Participants must meet the protocol's inclusion criteria for EGFR Mutation Positive Non-small Cell Lung Cancer. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07315113 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-07

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer (NCT07315113)

A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Nuvectis Pharma, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (5 items).

Location: Maryland Oncology Hematology — Calverton, Maryland

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Provide written informed consent.
18 years old or older.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Subject's cancer has a known oncogenic driver alteration other than EGFR.
Known EGFR mutations that cause resistance to osimertinib
Known human epidermal growth factor receptor 2 (HER2) overexpression
Any contraindications to treatment with osimertinib

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (6 Sites)

Maryland Oncology Hematology — Calverton, Maryland
Massachusetts General Hospital — Boston, Massachusetts
Willamette Valley Cancer Institute and Research Center — Eugene, Oregon
UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
NEXT Houston — Houston, Texas
NEXT Virginia — Fairfax, Virginia

📞 Contact the Study Coordinator

Phone: (201) 627-8129

Email: ebelshaw@nuvectis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All EGFR Mutation Positive Non-small Cell Lung Cancer clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗